Market research
ARDX Ardelyx Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 12.9
- Dividend yield
- Not available
- Beta
- 0.73
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0396971071
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 12.9
- Dividend yield
- Not available
- Beta
- 0.73
About
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ARDX discussion.
5 years, 4 months ago
Ardelyx, Inc is currently in a long term uptrend where the price is trading 16.7% above its 200 day moving average.
From a valuation standpoint, the stock is 93.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 89.6.
Ardelyx, Inc's total revenue sank by 19.6% to $2M since the same quarter in the previous year.
Its net income has dropped by 45.9% to $-29M since the same quarter in the previous year.
Finally, its free cash flow fell by 55.6% to $-18M since the same quarter in the previous year.
Based on the above factors, Ardelyx, Inc gets an overall score of 2/5.